CMO/CDMO Biotechnology Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2032 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)

The global Contract Manufacturing Organization (CMO) and Contract Development and Manufacturing Organization (CDMO) biotechnology market is witnessing strong growth momentum as pharmaceutical and biopharmaceutical companies increasingly outsource development and manufacturing operations. The market is expected to grow from US$ 14.0 Bn in 2025 to US$ 32.0 Bn by 2032, at a robust CAGR of 12.54% during the forecast period.

Market Insights

CMOs and CDMOs offer essential services to biotech and pharmaceutical companies, ranging from cell-line development and bio-manufacturing to analytical testing, clinical supply, fill-finish, and packaging. As drug development becomes more complex, companies are turning to specialized external partners to reduce operational burdens and accelerate timelines. The stand-alone services segment, in particular, is gaining traction for its flexibility and cost-effectiveness, with growing demand for cell-line development and process optimization.

Key Drivers

The growth of the CMO/CDMO biotechnology market is primarily driven by the increasing demand for biologics, biosimilars, and personalized medicines. The surge in approvals for monoclonal antibodies and the expansion of biosimilar pipelines have led to greater outsourcing of production to CMOs with high-capacity biomanufacturing capabilities. Advanced technologies, including single-use bioreactors and continuous manufacturing systems, are enabling faster, more efficient operations with improved yields and lower contamination risks.

Another key factor is the strategic shift within pharma and biotech companies to focus on R&D and commercialization while outsourcing manufacturing to experienced CDMOs. This model enhances operational agility and reduces capital expenditure. Furthermore, the emergence of integrated CDMO models offering end-to-end solutions-from molecule development to commercial manufacturing-is reshaping the market Analysis.

Business Opportunities

With growing pressure to accelerate time-to-market, especially for biologics and vaccines, CDMOs are investing heavily in expanding their capabilities and capacity. Companies like Lonza, Samsung Biologics, and AGC Biologics are leading the way by deploying new technologies and entering strategic collaborations. The acquisition of Molecular Medicine S.p.A. by AGC Biologics and the launch of Lonza’s GSv9™ technology platform are examples of such initiatives.

Mid-sized CDMOs are particularly well-positioned due to their specialized offerings and flexibility, accounting for a significant share of the market. The rise of biosimilars, gene therapies, and cell-based therapies presents lucrative growth avenues for both emerging and established players.

Regional Outlook

The United States continues to lead the market in North America, backed by a mature biotech ecosystem, favorable regulatory environment, and significant investment in advanced biologics manufacturing. The increasing adoption of single-use technologies and the construction of multi-drug production facilities are supporting sustained growth.

In Europe, the United Kingdom remains a strong performer, supported by its focus on high-quality biopharmaceutical manufacturing services and strategic global partnerships. The region is seeing growing interest in gene and cell therapy services.

South Korea dominates the East Asian market, driven by its advanced development capabilities and technology investments. The country is emerging as a key hub for biologics manufacturing, with companies like Samsung Biologics introducing proprietary technologies to support rapid scale-up and improve yield consistency.

Key Players

The global CMO/CDMO biotechnology market is highly competitive, with key players focusing on expanding their global footprint, enhancing service offerings, and embracing innovation. Major players include:
• Patheon N.V.
• Catalent
• Samsung Biologics Co., Ltd
• Lonza
• Boehringer Ingelheim
• AGC Biologics, Inc.
• WuXi Biologics
• AbbVie Inc.
• Avid Bioservices, Inc.
• Fujifilm Diosynth Biotechnologies
• Rentschler Biopharma SE
• KBI Biopharma (JSR Corporation)
• Cytovance Biologics
• Xpress Biologic

These companies are prioritizing strategic partnerships, facility expansions, and new technology platforms to strengthen their market presence and meet growing global demand.

Market Segmentation

By Service
• Stand-alone Services
• Integrated Services

By Product
• Monoclonal Antibodies
• Recombinant Proteins
• Vaccines
• Others

By Expression System
• Mammalian
• Microbial
• Others

By Company Size
• Small
• Mid-sized
• Large

By Scale of Operations
• Clinical
• Commercial

By Region
• North America
• Latin America
• Europe
• East Asia
• South Asia & Pacific
• Middle East & Africa

Please note: Delivery Timelines - 5 working days. Show more